|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...2930313233343536373839...39313932» |
- Tyvyt (sintilimab) / Eli Lilly, Zepsun (donafenib) / Suzhou Zelgen
A single-arm, multicenter, phase II study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_482;
- Tevimbra (tislelizumab-jsgr) / BeiGene, Zepsun (donafenib) / Suzhou Zelgen
Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: a single-center, single-arm, phase 2 study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_481;
- Imfinzi (durvalumab) / AstraZeneca
Three-year survival, safety and extended long-term survivor (eLTS) analysis from the Phase 3 TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_480;
- Kaitanni (cadonilimab) / Akesobio
Neoadjuvant short-course radiotherapy combined with chemotherapy and cadonilimab for patients with locally advanced rectal cancer: A prospective, single-arm phase II trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_474;
- Tyvyt (sintilimab) / Eli Lilly, IBI-310 (ipilimumab biosimilar) / Innovent Biologics
A randomized, controlled, multicenter phase 3 study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer: Trial in Progress (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_473;
- Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Ambezhu (bevacizumab biosimilar) / Sinocelltech
Neoadjuvant CAPOX plus SCT510 (bevacizumab biosimilar) and pucotenlimab (HX008) in high-risk resectable colorectal liver metastases (CRLM): a multicenter, phase II study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_472;
- Keytruda (pembrolizumab) / Merck (MSD)
"Comparative Treatment between Pembrolizumab and Chemotherapy on Patients diagnosed with Mismatch Repair Deficient Colorectal Cancer: A Systematic Review and Meta-Analysis" (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_466;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Split-Course Hypofraction Radiotherapy Combined with Chemotherapy and Tislelizumab as Preoperative treatment for Locally Advanced Rectal Cancer: Interim Analysis of A Prospective, Single-Arm Phase II Trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_434;
- iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
Efficacy and safety of iparomlimab and tuvonralimab (QL1706) in untreated metastatic colorectal cancer (mCRC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_431;
- Opdivo (nivolumab) / BMS
Efficacy of Low-Dose Nivolumab in Advanced Carcinomas (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_429;
- Darzalex (daratumumab) / J&J, HLX15 (daratumumab biosimilar) / Fosun Pharma
A Randomised, Double-blind, Phase I Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of HLX15 and Daratumumab in Healthy Male Participants (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_421;
- Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) / Roche
Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002 (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_420;
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Palbociclib versus ribociclib in first-line therapy of patients with metastatic breast cancer: direct comparison in real-world practice. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_419;
- Kisqali (ribociclib) / Novartis
Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_413;
- Kisqali (ribociclib) / Novartis
Real-world safety and effectiveness of ribociclib in Korean patients with HR+/HER2- locally advanced or metastatic breast cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_405;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_396;
- Imfinzi (durvalumab) / AstraZeneca
Short-term Pre-OPerative Durvalumab in early small triple negative breast cancer patients (POP-Durva) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_395;
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab Vs Treatment of Physician's Choice (TPC) in Patients With TNBC Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_394;
- Opdivo (nivolumab) / BMS
Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_269;
- Opdivo (nivolumab) / BMS
A real-world phase IV superiority study among recurrent or advanced head and neck cancer patients prescribed with low-dose Nivolumab and triple metronomic chemotherapy versus Paclitaxel Carboplatin regimen (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_268;
- AiRuiKa (camrelizumab) / HLB Bio Group
Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II, single-arm study (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_263;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Efficacy and safety of Tislelizumab(T) combined with Gemcitabine and Cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_240;
- Hansizhuang (serplulimab) / Fosun Pharma, Fruzaqla (fruquintinib) / Takeda
Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_236;
- S-588210 / OncoTherapy, Shionogi, Imfinzi (durvalumab) / AstraZeneca
DURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_235;
- Imfinzi (durvalumab) / AstraZeneca
Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results (Hall 405) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_211;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Patient Reported Outcomes (PRO) in the Asian Subgroup of the RATIONALE-305 Study (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_206;
- Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
EDGE-Gastric Arm A1: Phase 2 study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_205;
- Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche
Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_201;
- | Qinlock (ripretinib) / Ono Pharma
Journal, Stroma, Metastases: Modern times call for modernized treatment strategies for advanced gastrointestinal stromal tumors. (Pubmed Central) - Sep 16, 2024
No abstract available
- || AiRuiKa (camrelizumab) / HLB Bio Group
Review, Journal, Metastases: Response to hepatic arterial infusion chemotherapy combined with camrelizumab and targeted therapy in advanced primary hepatic neuroendocrine carcinoma: a case report and literature review. (Pubmed Central) - Sep 16, 2024
Meanwhile, the patient received camrelizumab (200 mg, intravenously, q3w) apatinib (250 mg, oral, daily) within 7 days after the start of HAIC...PHNEC is a very rare tumor, and the treatment for its advanced type is controversial and remains to be standardized. HAIC combined with camrelizumab and targeted therapy may be an effective and safe therapeutic option for patients with PHNEC.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, Metastases: Spontaneous regression of advanced hepatocellular carcinoma following COVID-19 infection and vaccination: a case report and review of literature. (Pubmed Central) - Sep 16, 2024
The patient's response in the absence of systemic therapy further underscores the complexity of HCC management and prompts further investigation into the potential immunomodulatory effects of viral infections and vaccinations on cancer regression. Understanding these interactions could have implications for tailoring treatment approaches and improving outcomes in patients with advanced HCC.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Metastases: Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study. (Pubmed Central) - Sep 16, 2024
Chemotherapy with SOX (S-1 and oxaliplatin) regimen showed good efficacy and a favorable safety profile in advanced gastric cancer...Among the 25 patients, 22 (88%) experienced any-grade adverse events (AEs), and 7 (28%) patients experienced grade ?3 AEs. Camrelizumab plus SOX showed promising efficacy and an acceptable safety profile as the first-line treatment for advanced gastric cancer.
- | Entyvio (vedolizumab) / Takeda
Journal, Checkpoint inhibition: Corticosteroid-dependent immune checkpoint inhibitor-induced enterocolitis treated with vedolizumab: a case report. (Pubmed Central) - Sep 16, 2024
He later underwent surgery and HCC treatment, including appropriate management of ICI-induced enterocolitis, and achieved a complete pathological response. This report illustrates the valuable role of vedolizumab in treating ICI-induced enterocolitis that is refractory to corticosteroid treatment.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Tumor complete response and pyogenic liver abscess secondary to concurrent microwave ablation plus atezolizumab and bevacizumab in liver cancer: a case report. (Pubmed Central) - Sep 16, 2024
The use of multiple courses of antibiotics over a prolonged period did not appear to influence the effectiveness of atezolizumab and bevacizumab. Further studies are, however, needed to substantiate this finding.
- | Rituxan (rituximab) / Roche
Journal, IO biomarker: Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Sep 16, 2024
The application of rituximab has significantly enhanced the overall survival rates in patients with diffuse large B-cell lymphoma (DLBCL)...In addition, we revealed mutations in HIST2H2AB, BCL2, NRXN3, FOXO1, HIST1H1C, LYN and TBL1XR1 genes were only detected in initial diagnostic biopsies, mutations in the EBF1 gene were solely detected in the rrDLBCL patients. Collectively, this study elucidates some of the genetic mechanisms contributing to the progression of rrDLBCL and suggests that the presence of CD58 mutations might serve as a powerful predictive marker for relapse/refractory outcomes in primary DLBCL patients.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, Checkpoint inhibition: Stevens-Johnson syndrome and toxic epidermal necrolysis-like eruptions in patients treated with immune checkpoint inhibitors: a systematic review. (Pubmed Central) - Sep 16, 2024
Our study provides valuable insights into the epidemiology, clinical features, management strategies, and outcomes of ICI-induced SJS/TEN, underscoring the importance of vigilant monitoring and personalized risk assessment in oncology practice. Continued research efforts are essential to optimize patient outcomes and enhance the safety profile of ICIs in cancer therapy.
- | Rituxan (rituximab) / Roche
Journal: Immunoglobulin G4-related breast disease: two cases treated successfully with rituximab. (Pubmed Central) - Sep 16, 2024
Continued research efforts are essential to optimize patient outcomes and enhance the safety profile of ICIs in cancer therapy. No abstract available
- | Rituxan (rituximab) / Roche
Journal: Help or hindrance? Rituximab maintenance and COVID. (Pubmed Central) - Sep 16, 2024
No abstract available Not available.
- | Leukothera (leukotoxin) / Actinobac Biomed
Journal: Virulence and host specificity of staphylococci from Staphylococcus intermedius group of pigeon origin with an emphasis on Staphylococcus intermedius. (Pubmed Central) - Sep 15, 2024
We proved that pigeon strains carried genes encoding for exfoliative toxin SIET and leukotoxin Luk-I...Moreover, only S. intermedius was not able to invade canine keratinocytes at all. These findings highlight the complex interplay between SIG bacteria, and their hosts, underscoring the need for further research to understand the mechanisms of host adaptation and pathogenicity within this group.
- ||| Talvey (talquetamab-tgvs) / J&J
Review, Journal, Adverse events: Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma. (Pubmed Central) - Sep 15, 2024
P1, P2
Oncology nurses have specialized knowledge of treatment administration monitoring based on their participation in the MonumenTAL-1 trial. This review provides information for nurses in both the academic and community settings on how to monitor, counsel, and support patients, which will in turn improve patients' quality of life and overall survival.
- ||| Journal, Adverse events, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors. (Pubmed Central) - Sep 15, 2024
Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
- | Opdivo (nivolumab) / BMS
Journal, Checkpoint inhibition, Metastases: Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors. (Pubmed Central) - Sep 15, 2024
Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers. The advent of immune checkpoint inhibitors has led to a substantial improvement in the median overall survival of individuals diagnosed with metastatic renal cell carcinoma.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Retrospective data, Review, Journal, Metastases: Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Sep 15, 2024
In this meta-analysis of RCTs, ICI plus CTX demonstrated a significant association with improved survival at the expense of an increased risk of immune-related adverse events. Therefore, our findings suggest that this combination should be considered as an initial treatment for aUC in platinum-eligible patients who cannot receive EV-P.
- || pazopanib / Generic mfg., sunitinib / Generic mfg., Cabometyx (cabozantinib tablet) / Exelixis
Clinical data, Journal, Metastases: Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer. (Pubmed Central) - Sep 15, 2024
Therefore, our findings suggest that this combination should be considered as an initial treatment for aUC in platinum-eligible patients who cannot receive EV-P. This study demonstrates an association between PPIs and impaired PFS in mRCC patients given pazopanib and cabozantinib and recommends caution on their concomitant use.
- | Rituxan (rituximab) / Roche
Journal: Type B insulin resistance syndrome: a case report. (Pubmed Central) - Sep 15, 2024
This study demonstrates an association between PPIs and impaired PFS in mRCC patients given pazopanib and cabozantinib and recommends caution on their concomitant use. No abstract available
- || Review, Journal: New Insights of Target Therapy: Effects of Tyrosine Kinase Inhibitors on Male Gonadal Function: A Systematic Review. (Pubmed Central) - Sep 15, 2024
Potential fertility concerns can help minimize adverse effects and improve patient outcomes. Addressing the potential impact of TKIs on male fertility helps optimize cancer treatment and survival outcomes.
- | Lumakras (sotorasib) / Amgen
Journal, PD(L)-1 Biomarker: A case of hepatoid adenocarcinoma of the lung harboring KRAS G12C responded favorably to sotorasib. (Pubmed Central) - Sep 15, 2024
The patient died 1 month after cessation of sotorasib and 3 months after postoperative recurrence. We have encountered what we believe to be the first case of hepatoid adenocarcinoma of the lung with KRAS G12C mutation that responded favorably to treatment with sotorasib.
- | ragistomig (ABL503) - ABL Bio, I / Mab
Journal: Anti-4-1BB (Pubmed Central) - Sep 15, 2024
ABL503-a PD-L1 and 4-1BB dual-targeting bispecific antibody-elicits pronounced additive tumor growth inhibition, with increased infiltration and functionality of exhausted CD8+ T cells, which in turn enhances the anti-cancer effects of anti-PD-1 blockade. These promising findings suggest that ABL503 (TJ-L14B) in combination with PD-1 inhibitors will likely further enhance therapeutic benefit in clinical trials.
- | Darzalex (daratumumab) / J&J
Journal, IO biomarker: Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma. (Pubmed Central) - Sep 15, 2024
In MM patients with MRD, daratumumab treatment does not affect IRF-4 expression. IRF-4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti-CD38 therapy.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer. (Pubmed Central) - Sep 15, 2024
DEGs and their enriched pathways identified in CD4+ T cells and CD8+ T cells play important roles in the development of renal irAEs related to anti-PD-1 therapy. These findings offer fresh perspectives on the pathogenesis of renal damage caused by anti-PD-1 therapy.